Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights

Key Phase III Readouts Soon

 
• By Andrew McConaghie
  
Eli Lilly logo sign atop Lilly Biotechnology Center
Lilly's drug outperformed Novo's in a head-to-head in diabetes, but is now aiming for superiority in obesity treatment as well. • Source: Michael Vi / Shutterstock.com
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip